Literature DB >> 28576676

Targeting PIK3CA-mutant advanced breast cancer in the clinical setting.

Neha Chopra1, Nicholas C Turner2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28576676     DOI： 10.1016/S1470-2045(17)30430-8

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  5 in total

Review 1.  ER+ metastatic breast cancer: past, present, and a prescription for an apoptosis-targeted future.

Authors:  Brett Rozeboom; Nandini Dey; Pradip De
Journal:  Am J Cancer Res       Date:  2019-12-01       Impact factor: 6.166

Review 2.  Exploring Biomarkers of Phosphoinositide 3-Kinase Pathway Activation in the Treatment of Hormone Receptor Positive, Human Epidermal Growth Receptor 2 Negative Advanced Breast Cancer.

Authors:  Virginia G Kaklamani; Andrea L Richardson; Carlos L Arteaga
Journal:  Oncologist       Date:  2019-01-16

3.  A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB).

Authors:  Ingrid A Mayer; Aleix Prat; Daniel Egle; Sibel Blau; J Alejandro Pérez Fidalgo; Michael Gnant; Peter A Fasching; Marco Colleoni; Antonio C Wolff; Eric P Winer; Christian F Singer; Sara Hurvitz; Laura García Estévez; Peter A van Dam; Sherko Kümmel; Christoph Mundhenke; Frankie Holmes; Naveen Babbar; Laure Charbonnier; Ivan Diaz-Padilla; Florian D Vogl; Dalila Sellami; Carlos L Arteaga
Journal:  Clin Cancer Res       Date:  2019-02-05       Impact factor: 12.531

4.  Outcomes prediction in pre-operative radiotherapy locally advanced rectal cancer: leucocyte assessment as immune biomarker.

Authors:  Alexis Vallard; Max-Adrien Garcia; Peng Diao; Sophie Espenel; Guy de Laroche; Jean-Baptiste Guy; Majed Ben Mrad; Chloé Rancoule; David Kaczmarek; Thierry Muron; Gregoire Pigné; Jack Porcheron; Michel Peoc'h; Jean-Marc Phelip; Julien Langrand-Escure; Nicolas Magné
Journal:  Oncotarget       Date:  2018-04-27

5.  The efficacy and safety of targeted therapy plus fulvestrant in postmenopausal women with hormone-receptor positive advanced breast cancer: A meta-analysis of randomized-control trials.

Authors:  Gao Chanchan; Su Xiangyu; Shi Fangfang; Chen Yan; Gu Xiaoyi
Journal:  PLoS One       Date:  2018-09-20       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.